pyrazinamide has been researched along with Sensitivity and Specificity in 60 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB)." | 7.91 | Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, AS; Khan, MT; Malik, SI; Masood, N; Nadeem, T, 2019) |
| "A new, precise, and very selective method for increasing the impact and assessment of 3-nitrotyrosine (3-Nty) as a biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy (MHE) disease was developed." | 7.83 | Nano optical sensor binuclear Pt-2-pyrazinecarboxylic acid -bipyridine for enhancement of the efficiency of 3-nitrotyrosine biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy. ( Al-Radadi, NS; Attia, MS, 2016) |
| "Pyrazinamide is important in the treatment of tuberculosis." | 7.78 | Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. ( Boeree, MJ; Dekhuijzen, PN; Mulder, A; Simons, SO; van der Laan, T; van Ingen, J; van Soolingen, D, 2012) |
| "All tested methods in this preliminary study showed excellent sensitivity and specificity for the determination of pyrazinamide susceptibility of M." | 7.77 | Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, MH; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "The microscopic observation drug susceptibility assay (MODS) was evaluated to determine susceptibility to pyrazinamide in Mycobacterium tuberculosis, and compared with the broth microdilution method (BMM), absolute concentration method (ACM), and pyrazinamidase (PZase) determination." | 7.77 | Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, M; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "Pyrazinamide is a first-line drug for treating tuberculosis, but pyrazinamide resistance testing is usually too slow to guide initial therapy, so some patients receive inappropriate therapy." | 7.75 | Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. ( Caviedes, L; Evans, CA; Gilman, RH; Méndez, M; Moore, DA; Peña, L; Sheen, P; Zhang, Y; Zimic, MJ, 2009) |
| "Resistance of Mycobacterium tuberculosis to pyrazinamide (PZA) derives mainly from mutations in the pncA gene." | 7.74 | Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. ( Augustynowicz-Kopec, E; Kato, S; Kirikae, F; Kirikae, T; Kobayashi, I; Miyoshi-Akiyama, T; Mori, T; Morita, K; Nakamura, T; Sekiguchi, J; Suetake, T; Yoshida, H; Zwolska, Z, 2007) |
| "To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis." | 7.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| "Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB)." | 3.91 | Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, AS; Khan, MT; Malik, SI; Masood, N; Nadeem, T, 2019) |
| "A new, precise, and very selective method for increasing the impact and assessment of 3-nitrotyrosine (3-Nty) as a biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy (MHE) disease was developed." | 3.83 | Nano optical sensor binuclear Pt-2-pyrazinecarboxylic acid -bipyridine for enhancement of the efficiency of 3-nitrotyrosine biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy. ( Al-Radadi, NS; Attia, MS, 2016) |
| "Pyrazinamide is important in the treatment of tuberculosis." | 3.78 | Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. ( Boeree, MJ; Dekhuijzen, PN; Mulder, A; Simons, SO; van der Laan, T; van Ingen, J; van Soolingen, D, 2012) |
| "All tested methods in this preliminary study showed excellent sensitivity and specificity for the determination of pyrazinamide susceptibility of M." | 3.77 | Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, MH; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "The microscopic observation drug susceptibility assay (MODS) was evaluated to determine susceptibility to pyrazinamide in Mycobacterium tuberculosis, and compared with the broth microdilution method (BMM), absolute concentration method (ACM), and pyrazinamidase (PZase) determination." | 3.77 | Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, M; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "By using the BACTEC 460TB system as the reference test, the sensitivity and specificity of the CONRAS-liquid test (100 mg/L pyrazinamide) tested on 75 M." | 3.76 | Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay. ( Grewal, HM; Syre, H; Øvreås, K, 2010) |
| "Pyrazinamide is a first-line drug for treating tuberculosis, but pyrazinamide resistance testing is usually too slow to guide initial therapy, so some patients receive inappropriate therapy." | 3.75 | Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. ( Caviedes, L; Evans, CA; Gilman, RH; Méndez, M; Moore, DA; Peña, L; Sheen, P; Zhang, Y; Zimic, MJ, 2009) |
| "Resistance of Mycobacterium tuberculosis to pyrazinamide (PZA) derives mainly from mutations in the pncA gene." | 3.74 | Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. ( Augustynowicz-Kopec, E; Kato, S; Kirikae, F; Kirikae, T; Kobayashi, I; Miyoshi-Akiyama, T; Mori, T; Morita, K; Nakamura, T; Sekiguchi, J; Suetake, T; Yoshida, H; Zwolska, Z, 2007) |
| "To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis." | 3.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| "Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available." | 2.82 | Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System. ( Almeida, D; Demers, AM; Diacon, AH; Dorasamy, A; Eisenach, KD; Everitt, D; Friedrich, SO; Gibson, M; Jentsch, U; Jugheli, L; Mapamba, D; Rojas-Ponce, G; Sasamalo, M; Venter, A, 2016) |
| "Pyrazinamide (PZA) is a key antibiotic for the treatment of drug susceptible tuberculosis." | 1.51 | Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis. ( Andres, S; Beckert, P; Dachsel, B; Feuerriegel, S; Havlicek, J; Labugger, I; Merker, M; Niemann, S; Slickers, P, 2019) |
| "Pyrazinamide (PZA) is a crucial first-line tuberculosis (TB) drug recommended for both drug-susceptible and multidrug-resistant Mycobacterium tuberculosis." | 1.48 | Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. ( Chen, J; Jin, J; Liu, W; Shen, Y; Sun, F; Wu, J; Wu, Y; Xie, L; Zhang, W; Zhang, Y, 2018) |
| "The sensitivity and specificity were 90." | 1.40 | Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. ( Barnard, M; Bosman, ME; Diacon, A; Hepple, JA; Maharaj, K; Mendel, CM; Pym, AS; Streicher, EM; Van Heerden, C; van Helden, PD; Warren, RM; York, T, 2014) |
| "Pyrazinamide (PZA) is an important drug in the treatment of tuberculosis." | 1.38 | A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis. ( Cotrina, M; Fuentes, P; Gilman, RH; Gutierrez, A; Kirwan, D; Loli, S; Sheen, P; Zimic, M, 2012) |
| "Therapeutic drug monitoring allows to determine the best dosage regimen adapted to each patient optimizing the therapeutic benefits, while minimizing the risk for side effects." | 1.36 | Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF. ( Ascenzi, P; Bevilacqua, N; Gullotta, F; Lauria, FN; Mancone, C; Notari, S; Pucillo, LP; Sergi, M; Tempestilli, M; Tripodi, M; Urso, R, 2010) |
| "Pyrazinamide (PZA) is an important first-line antituberculosis drug because of its sterilizing activity against semidormant tubercle bacilli." | 1.34 | Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. ( Chauhan, DS; Das, R; Faujdar, J; Gupta, P; Gupta, UD; Jadaun, GP; Katoch, VM; Malonia, SK; Mishra, AK; Sharma, P; Sharma, VD; Singh, K; Singh, P; Upadhyay, P; Venkatesan, K; Wesley, C, 2007) |
| "Trifluoroacetic acid (TFA) is a commonly used additive in HPLC and LC-MS analysis of basic compounds." | 1.33 | Simple means to alleviate sensitivity loss by trifluoroacetic acid (TFA) mobile phases in the hydrophilic interaction chromatography-electrospray tandem mass spectrometric (HILIC-ESI/MS/MS) bioanalysis of basic compounds. ( Naidong, W; Shou, WZ, 2005) |
| "In total, 45 children with pulmonary tuberculosis participated." | 1.32 | Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests. ( Gultekin, D; Kayaalp, N; Palanduz, A, 2003) |
| "Ethambutol was recovered from human urine quantitatively and stable for a period of at least one week in urine stored at -20 degrees C." | 1.32 | Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid. ( Bhagavathy, S; Gayathri, TN; Gurumurthy, P; Venkatesan, P, 2004) |
| "A simple and accurate liquid chromatographic method was developed and validated for estimation of isoniazid (ISN), pyrazinamide (PYR) and rifampicin (RIF) in combined dosage forms." | 1.31 | Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation. ( Caccialanza, G; Calleri, E; De Lorenzi, E; Furlanetto, S; Massolini, G, 2002) |
| "Tuberculous Meningitis is associated with a high morbidity and mortality if there is a delay in diagnosis." | 1.31 | Diagnostic criteria for Tuberculous Meningitis. ( Seth, R; Sharma, U, 2002) |
| "Although relapse was more frequent in patients with positive smears than those with negative smears (9." | 1.30 | Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? ( Bechan, S; Connolly, C; Short, GM; Standing, E; Wilkinson, D, 1998) |
| " Due to difficulties in producing effective combined formulations of these three drugs, the bioavailability of new combination formulations needs to be assessed prior to registration." | 1.30 | Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. ( Fredericks, A; Smith, PJ; van Dyk, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (11.67) | 18.2507 |
| 2000's | 22 (36.67) | 29.6817 |
| 2010's | 30 (50.00) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Wu, L | 1 |
| Ye, Z | 1 |
| Liu, H | 1 |
| Guo, H | 1 |
| Lin, J | 1 |
| Zheng, L | 1 |
| Chu, N | 1 |
| Liu, X | 1 |
| Liu, W | 1 |
| Chen, J | 2 |
| Shen, Y | 1 |
| Jin, J | 1 |
| Wu, J | 1 |
| Sun, F | 1 |
| Wu, Y | 1 |
| Xie, L | 1 |
| Zhang, Y | 3 |
| Zhang, W | 1 |
| Bouzouita, I | 1 |
| Cabibbe, AM | 1 |
| Trovato, A | 1 |
| Draoui, H | 1 |
| Ghariani, A | 1 |
| Midouni, B | 1 |
| Essalah, L | 1 |
| Mehiri, E | 1 |
| Cirillo, DM | 1 |
| Slim-Saidi, L | 1 |
| Aono, A | 1 |
| Chikamatsu, K | 1 |
| Yamada, H | 1 |
| Igarashi, Y | 1 |
| Murase, Y | 1 |
| Takaki, A | 1 |
| Mitarai, S | 1 |
| Khan, MT | 1 |
| Malik, SI | 1 |
| Ali, S | 1 |
| Masood, N | 1 |
| Nadeem, T | 1 |
| Khan, AS | 1 |
| Afzal, MT | 1 |
| Havlicek, J | 1 |
| Dachsel, B | 1 |
| Slickers, P | 1 |
| Andres, S | 1 |
| Beckert, P | 1 |
| Feuerriegel, S | 1 |
| Niemann, S | 1 |
| Merker, M | 1 |
| Labugger, I | 1 |
| Hong, CY | 1 |
| Wang, F | 1 |
| Liu, XL | 1 |
| Li, H | 2 |
| Zhou, M | 1 |
| Geng, X | 1 |
| Yu, J | 1 |
| Wang, W | 1 |
| Zhang, XE | 1 |
| Wei, H | 1 |
| Cheemalapati, S | 1 |
| Devadas, B | 1 |
| Chen, SM | 1 |
| Streicher, EM | 1 |
| Maharaj, K | 1 |
| York, T | 1 |
| Van Heerden, C | 1 |
| Barnard, M | 1 |
| Diacon, A | 1 |
| Mendel, CM | 1 |
| Bosman, ME | 1 |
| Hepple, JA | 1 |
| Pym, AS | 1 |
| Warren, RM | 1 |
| van Helden, PD | 1 |
| Mathys, V | 1 |
| van de Vyvere, M | 1 |
| de Droogh, E | 1 |
| Soetaert, K | 1 |
| Groenen, G | 1 |
| Rienthong, S | 1 |
| Boonin, C | 1 |
| Chaiyasirinrote, B | 1 |
| Satproedprai, N | 1 |
| Mahasirimongkol, S | 1 |
| Yoshida, H | 2 |
| Kondo, Y | 1 |
| Namwat, C | 1 |
| Rienthong, D | 1 |
| Maningi, NE | 1 |
| Daum, LT | 1 |
| Rodriguez, JD | 1 |
| Mphahlele, M | 1 |
| Peters, RP | 1 |
| Fischer, GW | 1 |
| Chambers, JP | 1 |
| Fourie, PB | 1 |
| Demers, AM | 1 |
| Venter, A | 1 |
| Friedrich, SO | 1 |
| Rojas-Ponce, G | 1 |
| Mapamba, D | 1 |
| Jugheli, L | 1 |
| Sasamalo, M | 1 |
| Almeida, D | 1 |
| Dorasamy, A | 1 |
| Jentsch, U | 1 |
| Gibson, M | 1 |
| Everitt, D | 1 |
| Eisenach, KD | 1 |
| Diacon, AH | 1 |
| Zhou, LP | 1 |
| Luo, J | 1 |
| Yu, JP | 1 |
| Yang, H | 1 |
| Wei, HP | 1 |
| Attia, MS | 1 |
| Al-Radadi, NS | 1 |
| Shenai, S | 1 |
| Ronacher, K | 1 |
| Malherbe, S | 1 |
| Stanley, K | 1 |
| Kriel, M | 1 |
| Winter, J | 1 |
| Peppard, T | 1 |
| Barry, CE | 2 |
| Wang, J | 1 |
| Dodd, LE | 1 |
| Via, LE | 1 |
| Walzl, G | 1 |
| Alland, D | 1 |
| Velásquez, GE | 1 |
| Calderon, RI | 1 |
| Mitnick, CD | 1 |
| Becerra, MC | 1 |
| Huang, CC | 1 |
| Zhang, Z | 1 |
| Contreras, CC | 1 |
| Yataco, RM | 1 |
| Galea, JT | 1 |
| Lecca, LW | 1 |
| Murray, MB | 1 |
| Piersimoni, C | 1 |
| Mustazzolu, A | 1 |
| Iacobino, A | 1 |
| Giannoni, F | 1 |
| Santoro, G | 1 |
| Gherardi, G | 1 |
| Del Giudice, A | 1 |
| Perna, R | 1 |
| Fattorini, L | 1 |
| Herrera-León, L | 1 |
| Pozuelo-Díaz, R | 1 |
| Molina Moreno, T | 1 |
| Valverde Cobacho, A | 1 |
| Saiz Vega, P | 1 |
| Jiménez Pajares, MS | 1 |
| Sheen, P | 2 |
| Méndez, M | 1 |
| Gilman, RH | 2 |
| Peña, L | 1 |
| Caviedes, L | 1 |
| Zimic, MJ | 1 |
| Moore, DA | 1 |
| Evans, CA | 1 |
| Ang, M | 1 |
| Htoon, HM | 1 |
| Chee, SP | 1 |
| Syre, H | 1 |
| Øvreås, K | 1 |
| Grewal, HM | 1 |
| Mackensen, F | 1 |
| Becker, M | 1 |
| Zimmermann, S | 1 |
| Notari, S | 1 |
| Mancone, C | 1 |
| Sergi, M | 1 |
| Gullotta, F | 1 |
| Bevilacqua, N | 1 |
| Tempestilli, M | 1 |
| Urso, R | 1 |
| Lauria, FN | 1 |
| Pucillo, LP | 1 |
| Tripodi, M | 1 |
| Ascenzi, P | 1 |
| Basu, S | 1 |
| Padhi, TR | 1 |
| Su, WJ | 1 |
| Feng, JY | 1 |
| Chiu, YC | 1 |
| Huang, SF | 1 |
| Lee, YC | 1 |
| Mirabal, NC | 1 |
| Yzquierdo, SL | 1 |
| Lemus, D | 1 |
| Madruga, M | 1 |
| Milián, Y | 1 |
| Echemendía, M | 1 |
| Takiff, H | 2 |
| Martin, A | 2 |
| Van der Stuyf, P | 1 |
| Palomino, JC | 2 |
| Montoro, E | 1 |
| Zhou, Z | 1 |
| Chen, L | 1 |
| Liu, P | 1 |
| Shen, M | 1 |
| Zou, F | 1 |
| Campanerut, PA | 2 |
| Ghiraldi, LD | 2 |
| Spositto, FL | 2 |
| Sato, DN | 2 |
| Leite, CQ | 2 |
| Hirata, MH | 1 |
| Hirata, RD | 2 |
| Cardoso, RF | 2 |
| Hirata, M | 1 |
| Simons, SO | 1 |
| van Ingen, J | 1 |
| van der Laan, T | 1 |
| Mulder, A | 1 |
| Dekhuijzen, PN | 1 |
| Boeree, MJ | 1 |
| van Soolingen, D | 1 |
| Zimic, M | 1 |
| Loli, S | 1 |
| Gutierrez, A | 1 |
| Fuentes, P | 1 |
| Cotrina, M | 1 |
| Kirwan, D | 1 |
| Llorenç, V | 1 |
| González-Martin, J | 1 |
| Keller, J | 1 |
| Rey, A | 1 |
| Pelegrín, L | 1 |
| Mesquida, M | 1 |
| Adán, A | 1 |
| Calleri, E | 1 |
| De Lorenzi, E | 1 |
| Furlanetto, S | 1 |
| Massolini, G | 1 |
| Caccialanza, G | 1 |
| Jasmer, RM | 1 |
| Nahid, P | 1 |
| Hopewell, PC | 1 |
| Jindani, A | 1 |
| Doré, CJ | 1 |
| Mitchison, DA | 2 |
| Palanduz, A | 1 |
| Gultekin, D | 1 |
| Kayaalp, N | 1 |
| Wade, MM | 1 |
| Volokhov, D | 1 |
| Peredelchuk, M | 1 |
| Chizhikov, V | 1 |
| Gurumurthy, P | 1 |
| Gayathri, TN | 1 |
| Bhagavathy, S | 1 |
| Venkatesan, P | 1 |
| Johansen, IS | 1 |
| Thomsen, VØ | 1 |
| Marjamäki, M | 1 |
| Sosnovskaja, A | 1 |
| Lundgren, B | 1 |
| Shou, WZ | 1 |
| Naidong, W | 1 |
| Vandamme, P | 1 |
| Swings, J | 1 |
| Portaels, F | 1 |
| Singh, P | 1 |
| Wesley, C | 1 |
| Jadaun, GP | 1 |
| Malonia, SK | 1 |
| Das, R | 1 |
| Upadhyay, P | 1 |
| Faujdar, J | 1 |
| Sharma, P | 1 |
| Gupta, P | 1 |
| Mishra, AK | 1 |
| Singh, K | 1 |
| Chauhan, DS | 1 |
| Sharma, VD | 1 |
| Gupta, UD | 1 |
| Venkatesan, K | 1 |
| Katoch, VM | 1 |
| Glass, BD | 1 |
| Agatonovic-Kustrin, S | 1 |
| Chen, YJ | 1 |
| Wisch, MH | 1 |
| Sekiguchi, J | 1 |
| Nakamura, T | 1 |
| Miyoshi-Akiyama, T | 1 |
| Kirikae, F | 1 |
| Kobayashi, I | 1 |
| Augustynowicz-Kopec, E | 1 |
| Zwolska, Z | 1 |
| Morita, K | 1 |
| Suetake, T | 1 |
| Kato, S | 1 |
| Mori, T | 1 |
| Kirikae, T | 1 |
| Miller, MA | 1 |
| Thibert, L | 1 |
| Desjardins, F | 1 |
| Siddiqi, SH | 1 |
| Dascal, A | 1 |
| Stevens, JP | 1 |
| Daniel, TM | 1 |
| McColloster, P | 1 |
| Neff, NE | 1 |
| Argekar, AP | 1 |
| Kunjir, SS | 1 |
| Purandare, KS | 1 |
| Wilkinson, D | 1 |
| Bechan, S | 1 |
| Connolly, C | 1 |
| Standing, E | 1 |
| Short, GM | 1 |
| Gangadharam, PR | 1 |
| Geeta, N | 1 |
| Hsu, YY | 1 |
| Wise, DL | 1 |
| Smith, PJ | 1 |
| van Dyk, J | 1 |
| Fredericks, A | 1 |
| Davies, AP | 1 |
| Billington, OJ | 1 |
| McHugh, TD | 1 |
| Gillespie, SH | 1 |
| Tortoli, E | 1 |
| Mattei, R | 1 |
| Savarino, A | 1 |
| Bartolini, L | 1 |
| Beer, J | 1 |
| Teyssier, L | 1 |
| Khuhawar, MY | 1 |
| Rind, FM | 1 |
| Seth, R | 1 |
| Sharma, U | 1 |
| LaBombardi, VJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis[NCT02371681] | Phase 2 | 262 participants (Actual) | Interventional | 2015-02-25 | Completed | ||
| Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pyrazinamide and Sensitivity and Specificity
| Article | Year |
|---|---|
Clinical practice. Latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Male; Practice Guideline | 2002 |
Outpatient management of tuberculosis.
Topics: Algorithms; Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Drug Interactions; | 1996 |
1 trial available for pyrazinamide and Sensitivity and Specificity
| Article | Year |
|---|---|
Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2016 |
57 other studies available for pyrazinamide and Sensitivity and Specificity
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Calibration; Chromatography, High Pres | 2020 |
Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; China; Genotype; Humans; | 2018 |
Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2018 |
A simplified pyrazinamidase test for pyrazinamide drug susceptibility in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Culture Media; Diagnostic Tests, Routine; Drug Resistance, B | 2018 |
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Antitubercular Agents; Child; Drug Resistance, Bacterial; | 2019 |
Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Eswatini; Genotype; Humans; Microarray Analy | 2019 |
[Detection of pncA mutation associated with pyrazinamide resistance in Mycobacterium tuberculosis by high-resolution melting cure analysis].
Topics: Amidohydrolases; Antitubercular Agents; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Gen | 2013 |
Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approach.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Molecular Diagno | 2014 |
Highly sensitive and selective determination of pyrazinamide at poly-L-methionine/reduced graphene oxide modified electrode by differential pulse voltammetry in human blood plasma and urine samples.
Topics: Adult; Antitubercular Agents; Biosensing Techniques; Electrochemical Techniques; Electrodes; Electro | 2014 |
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Genotype; Genotyping Techniques; | 2014 |
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.
Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed R | 2014 |
Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand.
Topics: Antibiotics, Antitubercular; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Genotype; Hu | 2015 |
Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Genotyping Techniques; High-Thro | 2015 |
Rapid colorimetric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Colorimetry; Drug Resistance, Bacterial; Isoniazid; Microbial Sensitivity Tes | 2016 |
Nano optical sensor binuclear Pt-2-pyrazinecarboxylic acid -bipyridine for enhancement of the efficiency of 3-nitrotyrosine biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy.
Topics: Adult; Biomarkers; Early Diagnosis; Equipment Design; Equipment Failure Analysis; Female; Hepatic En | 2016 |
Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.
Topics: Antitubercular Agents; Area Under Curve; Bacterial Load; Bacteriological Techniques; Biomarkers; Eth | 2016 |
Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Amidohydrolases; Antitubercular Agents; Biological | 2016 |
Pyrazinamide susceptibility testing: proposed new standard with the BACTECTM MGITTM 960 system.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2016 |
[Differentiation of species within the Mycobacterium tuberculosis complex by molecular techniques].
Topics: Animals; Bacterial Proteins; Carboxylic Acids; Cattle; Chaperonin 60; DNA Gyrase; DNA, Bacterial; Hu | 2009 |
Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tes | 2009 |
Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Therapy, Combination; Enzyme-Linked Immunosorbe | 2009 |
Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay.
Topics: Antitubercular Agents; Colorimetry; Culture Media; Humans; Microbial Sensitivity Tests; Mycobacteriu | 2010 |
Tuberculous uveitis.
Topics: Antitubercular Agents; Area Under Curve; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assa | 2010 |
Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; Humans; Pyrazinamide; Reproducibility of Results | 2010 |
Tuberculous uveitis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Interfe | 2010 |
Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; | 2011 |
Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Colorimetry; Drug Resistance, Bacterial; Humans; Microbial S | 2010 |
Simultaneous determination of isoniazid, pyrazinamide, rifampicin and acetylisoniazid in human plasma by high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Isoniazid; Pyrazinamide; Rifampin; Sensit | 2010 |
Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay.
Topics: Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium | 2011 |
Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Microscopy; | 2011 |
Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Topics: Adolescent; Adult; Aged, 80 and over; Amidohydrolases; Antitubercular Agents; Female; Humans; Male; | 2012 |
A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Biological Transport; Biotransformation; Drug Resistance, Bacterial; Humans; | 2012 |
Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: from the tuberculin skin test to the new interferon gamma release assays.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination; | 2013 |
Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Isoniazid; Pharmaceu | 2002 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests.
Topics: Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administratio | 2003 |
Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray.
Topics: DNA, Bacterial; Drug Resistance, Bacterial; Gene Expression Profiling; Humans; Microbial Sensitivity | 2004 |
Standardization of the method for estimation of ethambutol in pharmaceutical preparations and biological fluid.
Topics: Antitubercular Agents; Chemistry, Clinical; Chromatography; Dose-Response Relationship, Drug; Ethamb | 2004 |
Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
Topics: Antitubercular Agents; Colony Count, Microbial; Culture Media; Drug Resistance, Multiple, Bacterial; | 2004 |
Simple means to alleviate sensitivity loss by trifluoroacetic acid (TFA) mobile phases in the hydrophilic interaction chromatography-electrospray tandem mass spectrometric (HILIC-ESI/MS/MS) bioanalysis of basic compounds.
Topics: Acetic Acid; Chromatography, Liquid; Cotinine; Ethionamide; Fluconazole; Humans; Isoniazid; Nicotine | 2005 |
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide.
Topics: Amidohydrolases; Antitubercular Agents; Colorimetry; DNA, Bacterial; Drug Resistance, Bacterial; Fal | 2006 |
Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Culture Media; Humans; Microbial Sensitivity Tests; Mycobact | 2007 |
Optimization of a stability-indicating HPLC method for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a fixed-dose combination using artificial neural networks.
Topics: Biological Availability; Chromatography, High Pressure Liquid; Drug Combinations; Hydrogen-Ion Conce | 2007 |
Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2007 |
Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay.
Topics: Antitubercular Agents; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Sensit | 1995 |
Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis.
Topics: Adult; Ciprofloxacin; Decision Support Techniques; Decision Trees; Health Personnel; HIV Seronegativ | 1995 |
Simultaneous determination of rifampicin, isoniazid and pyrazinamid by high performance thin layer chromatography.
Topics: Antitubercular Agents; Chromatography, Thin Layer; Drug Combinations; Isoniazid; Pyrazinamide; Repro | 1996 |
Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
Topics: Adult; Ambulatory Care; Antibiotics, Antitubercular; Antitubercular Agents; Cohort Studies; Confiden | 1998 |
Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
Topics: Administration, Oral; Analysis of Variance; Animals; Antitubercular Agents; Biocompatible Materials; | 1999 |
Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Humans; Isoniazid; Pyrazinamide; Rifamp | 1999 |
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Genotype; Humans; Microbial Sensitivity Tests; Mutation; Myc | 2000 |
Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Carbon Dioxide; Ethambutol; Humans; Isoniazid; M | 2000 |
Higher activity of morphazinamide over pyrazinamide against intracellular.
Topics: Antitubercular Agents; Humans; Isoniazid; Macrophages; Microbial Sensitivity Tests; Mycobacterium tu | 2001 |
Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Humans; Isoniazid; Pharmaceutical Prepa | 2002 |
Diagnostic criteria for Tuberculous Meningitis.
Topics: Antitubercular Agents; Child; Child, Preschool; Humans; Isoniazid; Mycobacterium tuberculosis; Progn | 2002 |
Comparison of the ESP and BACTEC systems for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide.
Topics: Animals; Antitubercular Agents; Cattle; Culture Media; Drug Resistance, Bacterial; Humans; Microbial | 2002 |